Skip to content

Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence

Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04930159
Acronym
SISTER
Enrollment
252
Registered
2021-06-18
Start date
2021-09-01
Completion date
2026-10-31
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial Cancer

Brief summary

The SISTER study is a randomized trial, looking at various modalities of social support for Black patients undergoing treatment for endometrial cancer. There are three study arms: group support, 1:1 peer support, and enhanced usual care. The primary outcome is treatment completion, and the secondary outcome is social isolation.

Detailed description

SISTER is a prospective, open randomized controlled trial of U.S. Black/African-American people with high-risk endometrial cancer requiring treatment with chemotherapy, radiation, or immunotherapy. We will compare social support interventions of enhanced usual care, weekly group-based support, and 1:1 peer support to determine the most effective option to improve treatment completion and decrease social isolation. The SISTER study comparators are based on multiple systematic reviews of peer support literature, input from the multi-stakeholder Steering Group of the Endometrial Cancer Action Network for African Americans (ECANA), two focus groups of Black women with EC, and cancer center leadership at selected enrollment sites. The core function of each comparator is to decrease social isolation for women on active treatment. Of the peer support intervention options available, the SISTER study includes the two that have the most data collected among Black women with cancer, have been most efficacious with regard to social isolation9 and treatment completion, and were enthusiastically supported by ECANA patient partners and focus group data.

Interventions

BEHAVIORALFacilitated group support

Weekly group gatherings where content will alternate between group conversation and focused topics (e.g., treatment side-effects, mental health, family dynamics, nutrition, financial hardship) with facilitated discussion by a trained professional in nutrition, psychotherapy, cognitive behavioral therapy, or medicine. Each group will cycle through the same order of topics.

BEHAVIORAL1:1 Peer Support

1:1 peer support via telephone or video either during or near a treatment visit. Call content will be focused on social support and driven by the needs of the participant.

Sponsors

University of Washington
Lead SponsorOTHER
Patient-Centered Outcomes Research Institute
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Adult 18 years of age or older; and 2. Self-identify as Black/African American 3. Presenting with high-risk EC established by anatomic pathology as tumor stage and grade classification by the following: 1. Pathology documentation from any hospital/clinic/medical center, and 2. FIGO Stage 1A with Grade 2, Grade 3, or Grade 4 of any histology type or 3. FIGO Stage 1A with non-endometrioid (carcinosarcoma, serous, clear cell, undifferentiated or mixed) histology 4. FIGO Stage 1B, 2, 3, or 4 of any grade or histology 5. Recurrent endometrial cancer of any stage or grade 4. Documented provider recommendation and patient plan to initiate adjuvant therapy with chemotherapy, radiation, and/or immunotherapy.

Exclusion criteria

Participants must not have any of the following

Design outcomes

Primary

MeasureTime frameDescription
Treatment completion (relative dose)6 monthsRelative dose is the ratio of actual-to-expected total dose of treatment received. The calculation of expected total dose will be made from the baseline treatment recommendation data collected at enrollment.

Secondary

MeasureTime frameDescription
Patient-reported social isolation (SPS-24)6 monthsThe Social Provisions Scale (SPS) is one of the most frequently used scales on social support, and is validated to measure the components of social support that directly impact health outcomes: attachment, social integration, reassurance of worth, reliable alliance, guidance, and opportunity for nurturance.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORKemi M Doll, MD, MS

University of Washington

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 29, 2026